Even when correcting for the larger tumor volume in Drp1‐cKO mice compared with control mice [13], we still observed a from 60% to ca. 20% in the efficacy of anti‐PD‐1 therapy in Drp1‐cKO mice (Fig. 4C). The gene discussed is PDCD1; the disease is neoplasm.